Mortality and morbidity of newly diagnosed heart failure treated with statins

Gomez-Soto, Francisco M.; Romero, Sotero P.; Bernal, J.A.; Escobar, Miguel A.; Puerto, José Luis; Andrey, José L.; Ruiz, Pedro A.; Gómez, Francisco

doi:10.1016/j.ijcard.2008.11.042

Cited by 15 publications

(11 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A few retrospective clinical studies have suggested that statins improve HFpEF, outcomes, possibly due to their pleiotropic and anti-inflammatory properties [102,103], but large benefits were not seen in a larger clinical trial with rosuvastatin [104] An ancillary study of the Digitalis Investigation Group Trial conducted between 1991 and 1993 found a trend toward a significant reduction in the combined primary endpoint of heart failure hospitalization or heart failure mortality among 988 HF patients and LVEF N45% treated with digoxin. While a benefit of digoxin in HFpEF through vagal tone modulation cannot be excluded, the use of digoxin cannot be advocated for at this time [105,106].…”

Section: Therapeutic Approach To Hfpefmentioning

confidence: 99%

Heart failure with preserved ejection fraction: Refocusing on diastole

Abbate

Arena

Abouzaki

et al. 2015

International Journal of Cardiology

View full text Add to dashboard Cite

Section: Therapeutic Approach To Hfpefmentioning

confidence: 99%

Heart failure with preserved ejection fraction: Refocusing on diastole

Abbate

Arena

Abouzaki

et al. 2015

International Journal of Cardiology

View full text Add to dashboard Cite

“…Additionally, several studies have found a survival benefit in patients with HFpEF who are receiving statin therapy [7,8,9], which mainly exerts a competitive inhibition on HMGR in the mevalonate pathway. The mevalonate pathway plays an important role in many cellular functions, including control of cell growth and differentiation by the synthesis of sterol isoprenoids such as cholesterol and non-sterol isoprenoids such as farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP) [10].…”

Section: Introductionmentioning

confidence: 99%

Alteration of Mevalonate Pathway Related Enzyme Expressions in Pressure Overload-Induced Cardiac Hypertrophy and Associated Heart Failure with Preserved Ejection Fraction

Chen

Zhong

Yang³

et al. 2013

Cell Physiol Biochem

View full text Add to dashboard Cite

Background: Abnormalities of the mevalonate pathway, an important cellular metabolic pathway, are common in many diseases including cardiovascular disease. The mevalonate pathway related enzyme expressions in pressure overload-induced cardiac hypertrophy and associated diastolic dysfunction remains largely unknown. This study aims to investigate whether the expression of mevalonate pathway related enzyme is altered during the progression of cardiac hypertrophy and associated diastolic dysfunction induced by pressure overload. Methods: Male Sprague-Dawley (SD) rats were randomly divided into two groups: the suprarenal abdominal aortic coarctation (AAC) group and the sham group. Results: Histological and echocardiographic assessments showed that there was a significant cardiovascular remodeling in the AAC group compared with the sham group after 3 weeks post-operatively, and the left ventricular (LV) diastolic function was reduced at 8 and 14 weeks post-operatively in the AAC group, without any change in systolic function during the study. The tissue of the heart and the abdominal aorta proximal to the coarctation showed over-expression of several enzymes, including 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGR), farnesyl diphosphate synthase (FDPS), farnesyltransferase-α (FNTA), farnesyltransferase-β (FNTB), geranylgeranyltransferase type I (GGTase-I) and the activation of their downstream proteins was enhanced. Conclusions: AAC induced compensatory LV hypertrophy to decompensatory diastolic dysfunction, accompanied by altered expression of several key enzymes in the mevalonate pathway.

show abstract

“…After full-text reviewing, 54 of the 69 articles were subsequently excluded from the meta-analysis (22 did not include data on clinical outcomes; five did not designate prognostic outcomes as primary or secondary endpoints; 10 were post-hoc analysis of randomised controlled trials; nine were retrospective studies; four lacked control groups; and four had other exclusion reasons). Eventually, 15 controlled studies were included in the analysis [16][17][18][19][20][21][22][23][24][25][26][27][28][29][30] (Fig. 1).…”

Section: Resultsmentioning

confidence: 99%